Context Therapeutics is a clinical-stage biopharmaceutical company developing T cell engaging (TCE) bispecific antibodies for solid tumors. TCE bispecific antibodies are engineered proteins that simultaneously bind to a target protein on a cancer cell and to CD3, a protein on T cells, redirecting the immune system to kill tumors. Context has three pipeline programs: CTIM-76, targeting Claudin 6 (CLDN6) in ovarian, endometrial, and testicular cancers (first patient dosed January 2025); CT-95, targeting Mesothelin (MSLN) in ovarian, pancreatic, and mesothelioma cancers (first patient dosed April 2025); and CT-202, targeting Nectin-4 in bladder, colorectal, lung, and breast cancers (first patient dosing expected Q3 2026). All three programs are in Phase 1 clinical trials with no Phase 2 or Phase 3 data yet. Context acquired or licensed all three programs from third parties and outsources manufacturing to contract manufacturers, primarily Lonza. Context has no approved products, no product revenue, and funds operations through equity financing. If any program reaches commercialization, revenue would come from product sales net of licensor royalties, or from licensing or partnership deals with larger pharmaceutical companies.